Combination of alpha-synuclein aggregation inhibitor anle138b and ER stress inhibitor AMG PERK 44 increases neuroprotection in Parkinson's disease organoid model

This study demonstrates that combining the alpha-synuclein aggregation inhibitor anle138b with the ER stress inhibitor AMG PERK 44 significantly enhances neuroprotection in a Parkinson's disease organoid model by improving metabolic activity, reducing alpha-synuclein pathology and cell death, and restoring proteostasis.

The Gist

The Big Picture: A New Strategy for Parkinson's Disease

Imagine the brain as a bustling, high-tech city. In Parkinson's Disease (PD), a specific type of worker in this city (dopamine-producing neurons) starts dying off. This causes the city's traffic lights to fail, leading to the shaking and stiffness we associate with the disease.

The main culprit? A protein called Alpha-synuclein. Think of this protein as a piece of trash that, instead of being thrown away, gets sticky and clumps together with other pieces of trash. These clumps (called oligomers and aggregates) are toxic. They clog up the workers' offices and eventually kill the workers.

For a long time, scientists have tried two main strategies to fix this:

1. The Janitor Approach: Try to break up the trash clumps so they don't stick together.
2. The Stress-Relief Approach: The trash clumps cause the workers to panic (cellular stress). Try to calm the workers down so they don't give up and die.

This paper asks a simple question: What if we hire a team that does both at the same time?

---

The Experiment: Building a "Mini-Brain"

Instead of testing drugs on mice (which are very different from humans) or flat cells in a dish (which are too simple), the researchers built a 3D "Mini-Brain."

• The Analogy: Imagine taking a lump of clay (stem cells) and sculpting it into a tiny, working model of a human brain's midbrain (the part affected by Parkinson's).
• The Setup: They took these healthy mini-brains and deliberately "sickened" them. They added the sticky trash (alpha-synuclein clumps) and a chemical poison (6-OHDA) to mimic the disease.
• The Result: The mini-brains started acting like Parkinson's patients: the workers were dying, and the trash was piling up.

The Two "Super-Tools"

The researchers tested two specific drugs on these sick mini-brains:

1. Anle138b (The Janitor): This drug is designed to stop the trash from clumping together. It keeps the alpha-synuclein proteins separate and harmless.
2. AMG44 (The Stress-Relief Coach): When the trash clumps pile up, the cell's internal factory (the Endoplasmic Reticulum) gets overwhelmed and screams "Help!" This is called ER Stress. If the stress goes on too long, the cell decides to commit suicide (apoptosis). AMG44 is a coach that tells the factory to calm down and stop the panic, preventing the cell from killing itself.

The Findings: 1 + 1 = 3

The researchers tested the drugs in three ways:

1. Using just the Janitor (Anle138b).
2. Using just the Coach (AMG44).
3. Using both together.

The Results:

• Single Doses: Both drugs helped a little bit. The Janitor reduced the trash, and the Coach stopped some panic.
• The Combo: When they used both drugs together, the results were amazing.
  • More Life: The mini-brains were much healthier and more active.
  • Less Trash: The toxic clumps disappeared faster.
  • Less Panic: The cells stopped panicking and stopped killing themselves.
  • Restored Balance: The cell's internal factory was restored to a healthy, working state.

Why This Matters (The "Aha!" Moment)

The paper suggests a crucial insight: Fixing the trash isn't enough if the cell is already in a panic.

• The Metaphor: Imagine a house on fire (the trash clumps).
  • If you just throw water on the fire (Anle138b), you might stop the flames, but the house is still filled with smoke and panic.
  • If you just tell the family to stay calm (AMG44), they won't run out, but the house will still burn down.
  • The Solution: You need to put out the fire AND clear the smoke at the same time.

The researchers found that breaking up the trash clumps can sometimes actually make the cell panic more temporarily (like stirring up the ashes). By adding the stress-relief drug at the same time, they prevented that panic, allowing the cell to survive and recover.

The Bottom Line

This study didn't just prove that these drugs work; it proved that combining them works better than either one alone.

They used a sophisticated "Mini-Brain" model that is much closer to a real human brain than previous tests. This gives scientists hope that a combination therapy—hiring a Janitor and a Stress-Relief Coach simultaneously—could be the key to a future treatment that doesn't just hide the symptoms of Parkinson's, but actually stops the disease from destroying the brain.

In short: To save the brain, we need to clean up the mess and calm the nerves at the same time.

Technical Summary

1. Problem Statement

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the accumulation of misfolded $\alpha$-synuclein ($\alpha$-syn) in midbrain dopaminergic neurons, leading to cell death. Current therapies are purely symptomatic, with no disease-modifying treatments available.

• Pathophysiology: The accumulation of toxic $\alpha$-syn oligomers within the Endoplasmic Reticulum (ER) lumen triggers ER stress and the Unfolded Protein Response (UPR). Specifically, the UPR sensor PERK (PKR-like ER kinase) becomes activated. While initially protective, prolonged PERK activation leads to the phosphorylation of eIF2$\alpha$ and the upregulation of the pro-apoptotic factor CHOP, driving neuronal death.
• Therapeutic Gap:
  • Anti-aggregation agents (e.g., anle138b): While effective at reducing $\alpha$-syn oligomers, disrupting aggregates can sometimes induce cellular shock or fail to address the downstream ER stress already present in damaged cells.
  • PERK Inhibitors (e.g., AMG44): These can restore proteostasis and prevent apoptosis but do not directly clear the toxic protein aggregates causing the stress.
  • Model Limitations: Traditional 2D cell cultures and animal models often fail to recapitulate the complex human pathology, blood-brain barrier interactions, and chronic nature of PD, leading to high rates of translational failure.

Hypothesis: Combining an $\alpha$-syn aggregation inhibitor (anle138b) with a selective PERK inhibitor (AMG44) will provide synergistic neuroprotection by simultaneously targeting the root cause (aggregates) and the downstream consequence (ER stress-induced apoptosis) in a physiologically relevant human model.

2. Methodology

The study utilized a novel 3D human midbrain organoid model derived from induced pluripotent stem cells (iPSCs) to mimic sporadic PD.

• Organoid Generation: Human iPSCs (Cellartis®) were differentiated into midbrain organoids over 55 days, confirmed by markers for neuronal progenitors (FOXA2), dopaminergic neurons (TH), and glial cells (S100$\beta$).
• PD Induction: Organoids were treated with:
  • $\alpha$-syn Pre-formed Fibrils (PFFs): To seed endogenous $\alpha$-syn aggregation.
  • 6-Hydroxydopamine (6-OHDA): A neurotoxin to induce oxidative stress and dopaminergic cell death.
• Treatment Groups: PD organoids were treated with:
  1. Anle138b: An oligomer modulator (25 $\mu$M).
  2. AMG44: A selective PERK inhibitor (25 $\mu$M).
  3. Combination: Both drugs simultaneously.
  4. Controls: Vehicle (DMSO) and untreated PD organoids.
• Assessment Techniques:
  • Viability: CellTiter-Glo 3D assay (ATP quantification).
  • Aggregation & Phosphorylation: Immunofluorescence and Western Blot for total $\alpha$-syn, pSer129-$\alpha$-syn (pathological marker), and aggregated $\alpha$-syn.
  • Apoptosis: Flow cytometry using Annexin V-FITC/Propidium Iodide (AV/PI) staining.
  • Proteostasis: Western Blot and qRT-PCR for UPR markers: BiP (GRP78), p-eIF2$\alpha$, CHOP, XBP1s, and ATF6.

3. Key Contributions

• Novel Disease Model: Development and validation of a human midbrain organoid model that successfully recapitulates key PD hallmarks: $\alpha$-syn aggregation, pSer129 phosphorylation, and dopaminergic cell death.
• Synergistic Therapy: First demonstration that combining an anti-aggregation agent with a PERK inhibitor yields superior neuroprotection compared to monotherapy in a human 3D context.
• Mechanistic Insight: Elucidation of how dual-targeting shifts the UPR from a pro-apoptotic state (CHOP-driven) to a pro-survival state (BiP/XBP1/ATF6-driven) while maintaining physiological protein levels.
• Gene vs. Protein Discrepancy: Discovery that while AMG44 downregulates SNCA mRNA, anle138b upregulates it, yet the combination normalizes protein levels, suggesting complex post-transcriptional regulation.

4. Key Results

• Cell Viability: Both drugs individually increased metabolic activity in PD organoids. However, the combination therapy significantly outperformed single agents, resulting in the highest levels of metabolically active cells.
• Reduction of Pathological $\alpha$-syn:
  • PD organoids showed high levels of aggregated and pSer129-$\alpha$-syn.
  • Monotherapy reduced these levels partially.
  • Combination therapy significantly decreased pSer129-$\alpha$-syn and aggregation, restoring total $\alpha$-syn levels to near-control values (indicating a shift from aggregated to soluble forms).
• Apoptosis Reduction: Flow cytometry revealed a significant decrease in apoptotic cells only in the combination group. Single treatments showed a trend but were not statistically significant compared to the PD group.
• Modulation of UPR Pathways:
  • Pro-survival: The combination uniquely upregulated protective chaperones BiP and adaptive UPR branches XBP1s and ATF6 at both protein and mRNA levels.
  • Pro-apoptotic: The combination effectively downregulated the pro-apoptotic factor CHOP and reduced the p-eIF2$\alpha$/eIF2$\alpha$ ratio.
  • Partial Inhibition: Crucially, the drugs did not completely silence eIF2$\alpha$ phosphorylation or $\alpha$-syn expression, preserving essential physiological functions.
• Gene Expression: The combination normalized SNCA mRNA levels and significantly increased the expression of protective UPR genes (HSPA5, EIF2A, XBP1, ATF6) while suppressing the pro-apoptotic DDIT3 (CHOP) gene more effectively than monotherapies.

5. Significance

• Translational Potential: This study bridges the gap between 2D cell models and animal studies by using human-derived 3D organoids, offering a more accurate prediction of drug efficacy in human PD pathology.
• Disease-Modifying Strategy: The results support a "multi-pronged" therapeutic approach. Targeting only aggregation or only ER stress is insufficient; addressing both simultaneously creates a synergistic effect that halts neurodegeneration more effectively.
• Safety Profile: The study highlights the importance of partial inhibition. By fine-tuning rather than completely blocking PERK or $\alpha$-syn, the therapy avoids the toxicity associated with total pathway suppression (e.g., pancreatic toxicity seen with older PERK inhibitors) while maintaining cellular homeostasis.
• Future Directions: The findings provide a strong rationale for advancing the anle138b/AMG44 combination into in vivo animal models and eventually clinical trials, potentially offering the first disease-modifying therapy for Parkinson's disease.

Conclusion: The combination of anle138b and AMG44 represents a promising, synergistic strategy for PD treatment, effectively restoring proteostasis, reducing apoptosis, and clearing toxic aggregates in a human-relevant 3D model, thereby addressing the multifaceted nature of PD pathogenesis.